Vicus Therapeutics

Bristol-Myers aims to become an oncology powerhouse in the next five years. It's making the right steps, but the competitive landscape is more challenging than ever and the company is pressed for time

The repositioning of drugs for new clinical indications is becoming an increasingly prominent development strategy because it can reduce development risk as well as both the time and investment requir

Reprofiling drugs for hospital supportive care Harston Mill Harston, Cambridge CB22 7GG, UK Phone: +44 1223 875130 Web Site: www.acaciapharma.com Contact: Julian Gilbert, PhD, CEO Industry Segment: Dr

Repurposing generics for cancer-related conditions 55 Madison Avenue Suite 400 Morristown NJ 07960 Phone: (973) 285-3175 Fax: (973) 543-1407 Web Site: www.vicustherapeutics.com Contact: John Maki, P